Abstract Body: INTRODUCTION
Over 25 million Americans have obstructive sleep apnea (OSA), which has a prevalence of 26% and substantial DALYs owing to its relationship to chronic illnesses and morbidity. OSA may be treated with novel GLP-1 and GIP agonists that regulate obesity and metabolic function.

AIMS
The major goal of our research was to evaluate baseline and post-therapeutic apnea-hypopnea index (AHI) and Epworth Sleepiness Scale (ESS) in GLP-1 and GIP agonist patients (+/- CPAP) to routine care. We calculated weight loss benefits (mean BMI decrease and weight circumference change).

METHODS
PRISMA-compliant clinical trials were used for a systematic review and meta-analysis. We used MeSH keywords to find clinical trials on OSA outcomes with various GLP-1 and GIP analogues and standard treatment (CPAP) during the previous 10 years on PubMed, Ovid, Medline, and Clinicaltrials.gov. Non-clinical, non-English, non-full length, and non-human research were eliminated. We collected data on outcomes in Excel and translated baseline vs. post-intervention parameters into mean differences and standard deviations. Random effects models calculated weighted mean difference with 95% confidence interval and heterogeneity (I²) (α=0.05) to create forest plots highlighting the advantages of newer GLP-1/GIP analogs using RavMan 5.4.

RESULTS
Of 24 studies evaluated for outcomes, 8 were considered for quantitative analysis. We found GLP-1/GIP analogs (581 patients) were associated with a statistically significant reduction in AHI [-10.11 events per hour (-16.52 to -3.69), p=0.002, I²= 100%] compared to standard therapy (n=564). Meta-analysis of clinical trials (Idris et. and Blackman et al.) showed Exenatide and Liraglutide (n=182) were associated with a non-significant reduction of -2.61 [-7.87 to 2.65, p=0.33, I²= 89%] in ESS in compared with Placebo (n=179).

CONCLUSION
GLP-1/GIP agonists improve AHI and ESS reducing OSA severity in our meta-analysis. More clinical trials and prospective research should determine subgroup demographics, treatment classes, and dosages to assess the risk-benefit ratio and reduce OSA.